Table 4.
Comparison to other studies on IGABT for cervical cancer.
| Study | IGABT Technique | No. of Patients | Medan HR-CTV Volume (cm3) | Local Control | Overall Survival |
| Present study | CT | 135 | 42 | 90.7% (5-year) | 87.2% (5-year) |
| Potter et al. [8] | MRI | 1416 | 28 | 92% (5-year) | 74% (5-year) |
| Potter et al. [11] | MRI | 156 | Mean tumor size > 5 cm | 95% (3-year) | 68% (3-year) |
| Charra-Brunaud et al. [12] | MRI | 117 | 35.2 | 78.5% (2-year) | 74% (2-year) |
| Sturdza et al. [9] | CT/MRI | 731 | 37 | 89% (5-year) | 65% (5-year) |
| Horne et al. [19] | MRI | 239 | 31 | 90.8% (5-year) | 72.7% (5-year) |
| Gill et al. [20] | CT/MRI | 128 | 31 | 92% (2-year) | 85% (2-year) |
| Horeweg et al. [10] | CT/MRI | 155 | Mean tumor size 4.6 cm | 90.4% (5-year) | 65.9% (5-year) |